sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Navepegritide

Medicine

Navepegritide

YUVIWEL ® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • This indication is approved under accelerated approval based on an improvement in annualized growth velocity.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

What it is used for

YUVIWEL ® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Who should not take it

None.

Storing it

Storage and Handling

  • Store YUVIWEL refrigerated between 2°C to 8°C (36°F to 46°F). Store in the original packaging until time of use to protect from light. Do not freeze.
  • YUVIWEL can also be stored at room temperature up to 30°C (86°F) for up to 6 months and can be returned to refrigeration within the 6 months. Do not use YUVIWEL beyond the expiration date or 6 months after the date it was first removed from refrigeration (whichever is earlier).
  • Reconstituted YUVIWEL can be stored at room temperature up to 30°C (86°F) for up to 4 hours.
  • Discard unused reconstituted solution.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Navepegritide; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/navepegritide

APA 7th

sofidex. (2026, August 3). Navepegritide. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/navepegritide

AMA 11th

Navepegritide. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/navepegritide

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.